Author Archive: Roy Zwahlen

Roy Zwahlen

Roy is Associate Counsel at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his three kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.

Latest Posts

Academics Imagine a Better World: Find the Right Partner at the BIO

2016 BIO International Convention

Academic and research institutions from around the world are coming to the BIO International Convention in San Francisco to find partners to advance their discoveries from the bench to the bedside.  Representing more than 10% (more than 1,000) of the attendees, academic participants reflect the entire biotech collaboration interface including university researchers, entrepreneurs, licensing officers, and research collaboration and economic development staff.  The BIO International Convention presents a unique opportunity to meet with the entire Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

IP at the 2014 BIO International Convention

San Diego

Securing and maintaining intellectual property protection for the next generation of biotech innovation faces new challenges and opportunities.  Come learn about current issues and those just on the horizon before they affect your practice and your company. Keynote Speakers in the IP Track: Director General Francis Gurry, World Intellectual Property Organization Judge Randall R. Rader, United States Court of Appeals for the Federal Circuit Acting Director Michelle Lee, United States Patent and Trademark Office IP Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Nautilus v. Biosig, Baxter v. Fresenius and Limelight v. Akamai

Supreme Court

BIO weighed in on three Supreme Court cases in the last few months whose outcome could change the IP landscape for biotechnology companies. BIO’s amicus brief in Nautilus v. Biosig Instruments argues that the petitioner misrepresents the Federal Circuit’s definiteness test and seeks to litigate an issue not properly before this court.  Petitioner’s approach radically departs from established law and practice.  Finally the petitioner’s approach would destabilize the patent system as it would inject substantial Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Corporate-Sponsored University Research Valuable for Further Innovation

SBIR Reauthorization Moves Forward

New research published in Nature, Technology Transfer: Industry-funded academic inventions boost innovation, provides data undermining “assumptions that corporate-funded academic research is less accessible and useful to others.” After reviewing empirical evidence covering 20 years of inventions in the University of California system the authors find that: “Corporate-sponsored research is surprisingly valuable for further innovation. Data collected over 20 years at nine campuses and three national laboratories administered by the University of California show that corporate-sponsored Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Special 301: BIO Highlights Challenges in India


BIO recently testified before the U.S. government on the intellectual property challenges our members face in various markets around the world. Among other matters, BIO recommended that the U.S. government designate India as a Priority Foreign Country, a designation that would lead to the consideration of trade sanctions for treaty violations. Specifically, BIO testified: “In the healthcare space, only a few dozen innovative and patent protected medicines are on the market in India. Yet, in Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,